This is a major milestone for the company as we move towards the creation of a first in class, drug-device combination product for patients suffering from insomnia. We look forward to bringing a much-needed solution for patients to the market.
Clinical trial recruitment initiated and completed during COVID-19
The drug tested in the study will form part of a new combination product for patients with insomnia
Closed Loop Medicine Ltd, a healthcare company focused on developing drug + digital combination products, the next generation of pharmaceutical products announces that it has completed recruitment for its critical clinical trial in the development of its combination product CLM-IN01 for insomnia.
The company successfully completed dosing of all required participants with its proprietary drug, despite the trial being conducted in the midst of a COVID-19 lockdown.
The global sleep economy is expected to grow to $585 billion by 2024, yet very few solutions for insomnia are helping people sleep better. Insomnia is a condition that afflicts 10-15% of the adult population and is often a further complication in certain neurodegenerative conditions, cancer, anxiety, depression and women’s health.
The combination products being developed by Closed Loop Medicine transform a patient’s care by integrating drug therapy and digitally delivered care solutions.
Dr Hakim Yadi OBE, Chief Executive Officer & Co-Founder of CLM commented: “This is a major milestone for the company as we move towards the creation of a first in class, drug-device combination product for patients suffering from insomnia. We look forward to bringing a much-needed solution for patients to the market”.